http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6361995-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8d595ec481a2a081fed4aa2fd4ff52d8 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2500-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2503-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-70 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0676 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5088 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-071 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate | 2000-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2002-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c8912b6e0758f8b7fa6e28f2f29cd66b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dfc9532c893cf70a904614c68c748334 |
| publicationDate | 2002-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-6361995-B1 |
| titleOfInvention | Protection of pancreatic β-cells during islet isolation and assessment of islet viability and candidate diabetes drugs after islet isolation |
| abstract | Standard pancreatic islet isolation results in beta-cell toxicity due to nitric oxide and/or streptozotocin-like molecules that are generated during the isolation process. This toxicity can be limited by the addition of compounds that work through the glucosamine pathway in islets and/or by the addition of nitric oxide inhibitors. Unless prevented, this toxicity results in beta-cells being unable to properly respond to high glucose, glucosamine, N-acetylglucosamine, or streptozotocin by increasing their relative amount of O-glycosylated protein. Likewise, in order to assess islet viability or the effect of diabetes drugs on beta-cell function, islets that have been adequately protected during their isolation can be stimulated with low glucose, high glucose, glucosamine, N-acetylglucosamine, or streptozotocin with or without the drug(s) of interest present. By analyzing the pattern of islet protein O-glycosylation that occurs, one can determine whether the islets are viable and whether or not the candidate drug(s) might be useful in the treatment of diabetes. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03078630-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8030058-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8021853-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007003533-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6589995-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003180712-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003186948-A1 |
| priorityDate | 1999-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 218.